Prof Terpos speaks with ecancer at the 16th International Myeloma Workshop about the bone related complications seen with myeloma patients (MM) and how these are managed.
Approximately 80% of MM patients present with detectable lesions of osteolytic bone disease, meaning it is a critical consideration to the overall treatment and management of patients with multiple myeloma.
The current management of MM bone disease is based on the use of bisphosphonates and mainly Zoledronic Acid due to favourable study results.
In some patients with side effects such as renal impairments it is recommended to stop bisphosphonates, however new studies involving Denosumab suggest that a solution may be on its way.
ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.